Elizabeth Holmes, former CEO of the now-defunct blood-testing technology company Theranos, recently learned a harsh lesson on the complexities and
Continue Reading Pitfalls of Attorney-Client Privilege and Tips for Corporate Officers and Employees
The mRNA Patent and Competitive Landscape: Pioneers, Litigation Outlook and Big Pharma’s Next Moves (Part III)
In Part I of this series providing a summary of the mRNA IP and competitive landscape through one year of
Continue Reading The mRNA Patent and Competitive Landscape: Pioneers, Litigation Outlook and Big Pharma’s Next Moves (Part III)
Capsida Biotherapeutics Debuts with $140 Million of Capital for its AAV Gene Therapies
Capsida Biotherapeutics Inc.—a Thousand Oaks, CA-based emerging biotechnology company—recently emerged from stealth mode with $ 140 million in start-up capital
Continue Reading Capsida Biotherapeutics Debuts with $140 Million of Capital for its AAV Gene Therapies
The mRNA Patent and Competitive Landscape: Translate BIO; Arcturus; eTheRNA and Other Startups; and LNP Technology (Part II)
In Part I of this three-part series, we focused on three mRNA technology market players: BioNTech, Moderna and CureVac.
Continue Reading The mRNA Patent and Competitive Landscape: Translate BIO; Arcturus; eTheRNA and Other Startups; and LNP Technology (Part II)
Key Takeaways from Google’s Supreme Court Copyright Win Over Oracle
The Supreme Court’s recent landmark ruling in Google v. Oracle ended a decade-long legal battle between the tech giants, finding
Continue Reading Key Takeaways from Google’s Supreme Court Copyright Win Over Oracle
When Do My Patents Expire?
A patent gives the patent holder the right to exclude others from making, using, selling, offering to sell, or importing
Continue Reading When Do My Patents Expire?
The mRNA Patent and Competitive Landscape Through One Year of the COVID-19 Pandemic–Part I
Shortly after we posted about Moderna, Inc.’s October 2020 pledge not to enforce its COVID-19-related patents during the pandemic, the
Continue Reading The mRNA Patent and Competitive Landscape Through One Year of the COVID-19 Pandemic–Part I
Bigfoot Biomedical® Secures up to $57 Million in Financing from Madryn Asset Management
Bigfoot Biomedical®, a Milpitas, CA emerging company, recently announced that it has secured new financing of up to $57
Continue Reading Bigfoot Biomedical® Secures up to $57 Million in Financing from Madryn Asset Management
Intent-to-Use Applications: Pros and Cons
Owning a federal trademark registration provides the ability to exclude others from using a certain word or design in association
Continue Reading Intent-to-Use Applications: Pros and Cons
Patent Strategy Should Consider Examiner Incentives
Patent examiners operate under a complex network of production and quality incentives that influence the likelihood that an examiner will
Continue Reading Patent Strategy Should Consider Examiner Incentives